Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Gains from Sales and Divestitures (2021 - 2022)

TScan Therapeutics (TCRX) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $116870.0 as the latest value for Q4 2022.

  • Quarterly Gains from Sales and Divestitures fell 63.64% to $116870.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $116870.0 through Dec 2022, down 63.64% year-over-year, with the annual reading at $116870.0 for FY2022, 63.64% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2022 was $116870.0 at TScan Therapeutics, down from $321410.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $321410.0 in Q4 2021, with the low at $116870.0 in Q4 2022.